Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.66 |
| ▸ | AURKA | O14965 | 3/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.66 |
| ▸ | FLT3 | P36888 | 3/20 | 0.66 |
| ▸ | KDR | P35968 | 3/20 | 0.66 |
| ▸ | ABL1 | P00519 | 3/20 | 0.66 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.66 |
| ▸ | PLK4 | O00444 | 2/20 | 0.66 |
| ▸ | LCK | P06239 | 2/20 | 0.66 |
| ▸ | FYN | P06241 | 2/20 | 0.66 |
| ▸ | LYN | P07948 | 2/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.66 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.66 |
| ▸ | BTK | Q06187 | 2/20 | 0.66 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.66 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.66 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.66 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777303 | 1.00 | CSF1R (0.66) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL4812793 | 0.93 | AURKA (0.68) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL13987461 | 0.93 | AURKA (0.68) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL13987794 | 0.91 | AURKA (0.61) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL4795374 | 0.87 | AURKA (0.72) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL13987482 | 0.87 | AURKA (0.72) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL13987737 | 0.84 | AURKA (0.63) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL13987820 | 0.83 | AURKA (0.66) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL4816765 | 0.82 | AURKA (0.69) | CSF1RAURKAPDGFRBFLT3KDR | |
| SCHEMBL13987443 | 0.80 | AAK1 (1.00) | CSF1RAURKAPDGFRBFLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | CSF1R 921/4885AURKA 122/4885PDGFRB 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.